There are just so many great stories about the newest discoveries in the OCF news feed, I almost missed this one about Erbitux since it did not mention it in the title OCF - new therapies
[quote]Surprisingly negative results came from the phase III Radiation Therapy Oncology Group (RTOG) 0522 trial (N = 940), which showed no benefit to adding cetuximab to the radiation/cisplatin platform for front-line therapy of advanced head and neck squamous cell carcinoma....�RTOG 0522 was the study of the year in head and neck cancer. Unfortunately, it was flat-out negative,� Dr. Hayes noted....[/quote]
Conclusion: [quote]Even as a negative study, RTOG 0522 is practice-changing. �Many physicians have been treating with this regimen, assuming this study would be positive,� he said. �But we now have no data to support this.�[/quote]